MedTrace Logo

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

NCT03212261 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-11-10

Study results available
· View outcomes & findings →

Summary

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).

Conditions

Interventions

BEHAVIORAL

3RP-Lymphoma

An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.

Sponsors & Collaborators

  • American Cancer Society, Inc.

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Giselle K. Perez, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-03
Primary Completion
2018-06-30
Completion
2018-09-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03212261 on ClinicalTrials.gov